News Image

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: Mar 27, 2025

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending

Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025

Read more at globenewswire.com

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (12/10/2025, 6:30:29 PM)

After market: 4.62 +0.03 (+0.65%)

4.59

+0.13 (+2.91%)



Find more stocks in the Stock Screener

Follow ChartMill for more